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THE PROCOAGULANT ACTIVITY elicited
by some experimental tumours was re-
cently characterized as a Factor X-
activating enzyme (Curatolo et al., 1979)
and it was shown that this thromboplastic
activity was clearly different from the
Factor VII-dependent activity of most
other tissues (Gordon et al., 1975). Since
this activity appeared in serum-free media
of fibroblasts after chemical transforma-
tion, it was suggested that it might even
represent a marker ofmalignancy (Gordon
& Leewis, 1978).
Factor X-activating activity was deter-
mined in two established Lewis lung
carcinoma (3LL) cell lines which were free
of any contaminating host cells. Washed
cells from cultured primary tumours and
spontaneous lung metastases were trans-
ferred to serum-free media containing
unsupplemented Dulbecco's medium with-
out indicator and 20 mg/ml human Factor
IX complex (prepared by the Plasma
Fractionation Laboratory, The Churchill
Hospital, Oxford). Thispreparation (Batch
No. 9D1250) contained negligible amounts
ofFactorVII, 36 iu Factor IX, 52 u Factor
II and 30 u Factor X/ reconstituted
ml. The chromogenic substrate S-2222
(Kabi Vitrum Ltd, London) was added to
the culture medium in a final concentra-
tion of 1 mri. After 2 h of incubation the
optical density was read at 405 nm in a
spectrophotometer. Appropriate controls
consisted of cell-free as well as Factor X-
free samples. The positive control con-
tained 50 mg/ml Russell's Viper venom
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instead of tumour cells. The results were
expressed as arbitrary units derived from
the optical densities generated by 2 7 x ]05
cells; they are summarized in Table I. As
can be seen, only Russell's Viper venom,
which is known to be a potent direct
activator of Factor X, and tumour cells,
produced appreciable amounts of proteo-
lytic activity. There was no statistical
difference between the levels of Factor X
activator detected in cultured primary and
metastatic cells.
After transplantation of freshly sus-
pended 3LL cells derived from a primary
tumour into the upper thigh of 12 C57BL
mice, 6 animals were treated with the
vitamin K antagonist phenprocoumon
throughout tumour growth, as previously
described (Hilgard et al., 1977). Twelve
days after transplantation the primary
tumour was surgically removed and the
animals were allowed to survive until
Day 29. They were then killed and the
secondary lung tumours carefully excised.
The primary tumours, lung tumours and
fragments of abdominal muscle were
homogenized and sonicated in normal
saline. The protein content of each tissue
extract was adjusted to 20 g/l with saline.
all extracts were tested for clot-promoting
activity using Factor VII-, Factor VIII-
and Factor X-deficient human plasma as
described by Curatolo et al. (1979).
Table II gives the mean clotting times
obtained with different tissue extracts.
Considerable thromboplastic activity of
all tissues was found when tested inFACTOR X-ACTIVATING ACTIVITIES 643
TABLE I.-Factor X-activating activity
measured with chromogenic substrate in
arbitrary units derived from optical
densities (OD)
Test sample* Factor X OD units + s.e.
Culture medium + 0-4 + 0-04
Lung cells - 035 + 0 00
Primary cells - 0-14 +0-01
Russell's Viper venom + 2-00
Lung cells + 1-24 + 0-02
Primary cells + 1-09 + 0-06
* All test samples contained equal volumes of
culture medium.
TABLE II.-Clot-promoting activity of
various tissue extracts tested in human
plasma deficient in specific clottingfactors
Clotting times
(range in sec)
Plasma deficient in
Factor Factor Factor
VII VIII X
Muscle (control) 73-92 18-24 182-196
Muscle (phen)t 79-89 19-26 178-201
Primary tumour (control) 24-32 20-29 161-185
Primary tumour (phen)t 39-54* 25-38 171-212
Metastases (control) 26-35 22-36 190-213
Metastases (phen)t 44-63* 24-40 186-209
Saline 85-104 105-128 212-226
* Significantly different (P < 0-01) from corre-
sponding control.
t Phen=tissue from phenprocoumon-treated
animals.
Factor VIII-deficient plasma. In contrast,
none ofthe extracts showed activity when
added to Factor X-deficient plasma.
Distinct differences however were found
when these tissue extracts were tested in
Factor VII-deficient plasma; muscle ex-
tracts were almost inactive, whereas ex-
tracts from primary tumour and lung
metastases of untreated animals produced
very short clotting times. Extracts from
primary and secondary tumours derived
from phenprocoumon-treated animals,
however, showed considerably less enzyme
activity.
From the foregoing it is evident that
single-cell cultures from primary and
secondary 3LL show a Factor X-activating
activity when tested by chromogenic
substrates. A similar activity can be
found in aqueous extracts ofsolid tumours
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and metastases using test plasma with
specific clotting factor deficiencies. It is
interesting to note that phenprocoumon
treatment of the tumour-bearing animals
produced a significant decrease of Factor
X-activating activity, indicating that this
proteolytic enzyme is vitamin-K-depend-
ent. No significant differences between
primary and secondary tumours could be
established by either method.
The biological significance of the de-
scribed procoagulant activity in cancer
cells is unknown. Previous investigations
have shown that warfarin (Poggi et al.,
1978), phenprocoumon (Hilgard et al.,
1977) and diet-induced vitamin K de-
ficiency (Hilgard, 1977) inhibit primary
tumour growth as well as the formation of
spontaneous metastases of 3LL. The de-
creased synthesis of the procoagulant,
Factor X-activating activity in antico-
agulated and vitamin K-deficient animals
indicates that the presence ofthis enzyme
in tumour cells might facilitate the pri-
mary and metastatic growth of malignant
tumours. This assumption accords with
the current concept of the role of fibrin
formation in tumour growth (Roos &
Dingemans, 1979) and provides an addi-
tional rationale for the use of vitamin K
antagonists in cancer therapy.
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